手术视频
关于我们
联系我们
中心官网
泌尿系统常见疾病循证医学证据
首页
良性前列腺增生
泌尿系统感染
泌尿系统结石
前列腺炎
前列腺癌
膀胱肿瘤
肾癌
其他
首页
搜索结果
证据分类
良性前列腺增生
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
手术视频
调查问卷
泌尿系统感染
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
泌尿系统结石
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
前列腺炎
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
前列腺癌
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
膀胱肿瘤
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
肾癌
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
其他
病因/危险因素证据
诊断证据
治疗及预后证据
预防证据
临床路径
临床实践指南
搜索结果
按关键字
按标题
按关键词
按摘要
按作者
按期刊
共搜索到
180条
与
and
有关的结果
Endoscopic surveillance for bladder cancer: a systematic review of contemporary worldwide practices
2021 年 发布于
Bju International
91 卷 第 5 期
Russell B.
Kotecha P.
Thurairaja R.
Nair R.
Malde S.
Kumar P.
Khan M. S.
Biomarkers
Tumor/*urine
Humans
Ribonuclease
Pancreatic/*urine
Sensitivity
and
Specificity
Urinary Bladder Neoplasms/*diagnosis/urine
文献简介
原文链接
The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumour and benign prostatic hyperplasia: a systematic review and meta-analysis
2021 年 发布于
Urol Oncol
39 卷 第 1 期
Motlagh R. S.
Mori K.
Miura N.
Quhal F.
Aydh A.
Laukhtina E.
Pradere B.
Karakiewicz P. I.
Enikeev D. V.
Deuker M.
Shariat S. F.
Administration
Intravesical
BCG Vaccine/*adverse effects/*therapeutic use
Humans
Meta-Analysis as Topic
R
and
omized Controlled Trials as Topic
*Systematic Reviews as Topic
Urinary Bladder Neoplasms/*drug therapy
文献简介
原文链接
A systematic review and meta-analysis of radical cystectomy in the treatment of muscular invasive bladder cancer (MIBC)
2021 年 发布于
Annals of Oncology
39 卷 第 6 期
Zhao J.
Zhou L.
Pan Y.
Chen L.
Cystoscopy/*methods
Feasibility Studies
Humans
Liquid Biopsy/methods
Sensitivity
and
Specificity
*Spectrum Analysis
Raman
Urinary Bladder/diagnostic imaging/*pathology
Urinary Bladder Neoplasms/*diagnosis/pathology/urine
Urine/cytology
Bladder cancer
Raman spectroscopy
diagnosis
meta-analysis
optical
文献简介
原文链接
机器人辅助腹腔镜膀胱癌根治术后不同尿流改道围手术期及术后并发症的 Meta 分析
2021 年 发布于
Eur Urol Open Sci
11 卷 第 11 期
杜跃林
游成宇
王辉
韦堂墙
张小军
王安果
5-aminolaevulinic acid
cystectomy
cystoscopy
hexylaminolaevulinate
narrow-b
and
imaging
photodynamic diagnosis
commercial or financial relationships that could be construed as a potential
conflict of interest.
文献简介
原文链接
Dietary N-nitroso compounds intake and bladder cancer risk: A systematic review and meta-analysis
2021 年 发布于
Cancer Treat Res Commun
8 卷 第 11 期
SeyyedSalehi M. S.
Mohebbi E.
Sasanfar B.
Toorang F.
Zendehdel K.
Disease-Free Survival
*Dose Fractionation
Radiation
Humans
Neoplasm Recurrence
Local/epidemiology/pathology/*radiotherapy
Radiation Dose Hypofractionation/*st
and
ards
Risk Factors
Treatment Outcome
Urinary Bladder Neoplasms/epidemiology/pathology/*radiotherapy
文献简介
原文链接
Intravesical gemcitabine for non-muscle invasive bladder cancer
2021 年 发布于
Turk J Urol
53 卷 第 6 期
Han M. A.
Maisch P.
Jung J. H.
Hwang J. E.
Narayan V.
Cleves A.
Hwang E. C.
Dahm P.
Cystectomy/adverse effects/*methods
Disease-Free Survival
Follow-Up Studies
Humans
Incidence
Intraoperative Complications/*epidemiology/etiology
Length of Stay/statistics & numerical data
Neoplasm Recurrence
Local/*epidemiology/etiology/prevention & control
R
and
omized Controlled Trials as Topic
Urinary Bladder/*injuries/pathology/surgery
Urinary Bladder Neoplasms/mortality/pathology/*surgery
Bipolar
bladder tumors
meta-analysis
monopolar
transurethral resection
文献简介
原文链接
Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis
2021 年 发布于
European Urology
11 卷 第 6 期
Schuettfort V. M.
Pradere B.
Quhal F.
Mostafaei H.
Laukhtina E.
Mori K.
Motlagh R. S.
Fisch M.
D'Andrea D.
Rink M.
Gontero P.
Soria F.
Shariat S. F.
Urinary bladder neoplasms
adjuvant chemotherapy
meta-analysis
neoadjuvant chemotherapy (NAC)
form (available at http://dx.doi.org/10.21037/tau-20-571). Dr. XZ serves as an
unpaid editorial board member of Translational Andrology
and
Urology from Mar
2015 to Feb 2021. The other authors have no conflicts of interest to declare.
文献简介
原文链接
A Systematic Review of Outcome Reporting, Definition and Measurement Heterogeneity in Non-Muscle Invasive Bladder Cancer Effectiveness Trials of Adjuvant, Prophylactic Treatment After Transurethral Resection
2021 年 发布于
World J Urol
2 卷 第 3 期
Veskimae E.
Subbarayan S.
Campi R.
Carron D.
Omar M. I.
Yuan C.
Dimitropoulos K.
Van Hemelrijck M.
Bryan R. T.
N'Dow J.
Babjuk M.
Witjes J. A.
Sylvester R.
MacLennan S.
Adjuvants
Immunologic/administration & dosage
Administration
Intravesical
Antibiotics
Antineoplastic/administration & dosage/adverse effects
Antimetabolites
Antineoplastic/*administration & dosage/adverse effects
BCG Vaccine/administration & dosage
Bias
Cause of Death
Confidence Intervals
Deoxycytidine/administration & dosage/adverse effects/*analogs & derivatives
Disease Progression
Drug Administration Schedule
Humans
Mitomycin/administration & dosage/adverse effects
Neoplasm Recurrence
Local/*drug therapy/mortality/prevention & control
R
and
omized Controlled Trials as Topic
Saline Solution/administration & dosage
Urinary Bladder Neoplasms/*drug therapy/mortality/pathology/prevention & control
Gemcitabine
文献简介
原文链接
Value of tumour-infiltrating immune cells in predicting response to intravesical BCG in patients with non-muscle-invasive bladder cancer: a systematic review and meta-analysis
2021 年 发布于
British Journal of Surgery
37 卷 第 1 期
Kardoust Parizi M.
Shariat S. F.
Margulis V.
Mori K.
Lotan Y.
Aged
Cystectomy/adverse effects/*methods/statistics & numerical data
Humans
Male
Middle Aged
Postoperative Complications
Quality of Life
R
and
omized Controlled Trials as Topic
Robotic Surgical Procedures/adverse effects/*methods/statistics & numerical data
Treatment Outcome
Urinary Bladder Neoplasms/*surgery
文献简介
原文链接
Effectiveness of contrast-enhanced ultrasound for detecting the staging and grading of bladder cancer: a systematic review and meta-analysis
2021 年 发布于
World J Urol
39 卷 第 6 期
Ge X.
Lan Z. K.
Chen J.
Zhu S. Y.
Administration
Intravesical
Antibiotics
Antineoplastic/*administration & dosage
Antimetabolites
Antineoplastic/*administration & dosage
Deoxycytidine/administration & dosage/*analogs & derivatives
Humans
Mitomycin/*administration & dosage
Neoplasm Invasiveness
R
and
omized Controlled Trials as Topic
Urinary Bladder Neoplasms/*drug therapy/pathology
Gemcitabine
Bladder cancer
Meta-analysis
Mitomycin
Systematic evaluation
文献简介
原文链接
腹腔镜或机器人辅助膀胱癌根治术体腔内外原位新膀胱术疗效的 Meta 分析
2021 年 发布于
Bladder Cancer
205 卷 第 8 期
李子豪
Humans
Neoplasm Recurrence
Local/epidemiology/prevention & control
Peer Review
Prospective Studies
Urinary Bladder
*Urinary Bladder Neoplasms/surgery
bladder cancer
intravesical chemotherapy
irrigation
r
and
omized controlled trial
recurrence
文献简介
原文链接
Safety and Efficacy of Transurethral Resection of Bladder Tumour Comparing Spinal Anaesthesia to Spinal Anaesthesia with an Obturator Nerve Block: A Systematic Review and Meta-Analysis
2021 年 发布于
European Urology
100 卷 第 3 期
Krishan A.
Bruce A.
Khashaba S.
Abouelela M.
Ehsanullah S. A.
Administration
Intravesical
Antibiotics
Antineoplastic/administration & dosage/*therapeutic use
BCG Vaccine
Carcinoma
Transitional Cell/*drug therapy
Humans
Mitomycin/administration & dosage/*therapeutic use
R
and
omized Controlled Trials as Topic
Treatment Outcome
Urinary Bladder Neoplasms/*drug therapy
文献简介
原文链接
Effects of fluorescent light cystoscopy in non-muscle-invasive bladder cancer: A systematic review and meta-analysis
2021 年 发布于
Transl Androl Urol
39 卷 第 4 期
Sun J.
Ma X.
Shen H.
Liu B.
Cystectomy/adverse effects
Humans
Postoperative Complications/diagnosis/epidemiology/etiology
Risk Factors
*Robotic Surgical Procedures/adverse effects
*Robotics
Treatment Outcome
*Urinary Bladder Neoplasms/surgery
Urologic Surgical Procedures
*Urology
Complications
European Association of Urology guidelines
Outcome reporting
Robot-assisted radical cystectomy
St
and
ardised tool
文献简介
原文链接
Perioperative outcomes and safety of robotic vs open cystectomy: a systematic review and meta-analysis of 12,640 cases
2021 年 发布于
Journal of Clinical Oncology
10 卷 第 2 期
Clement K. D.
Pearce E.
Gabr A. H.
Rai B. P.
Al-Ansari A.
Aboumarzouk O. M.
Carcinoma
Transitional Cell/*diagnostic imaging/*pathology
Humans
*Multiparametric Magnetic Resonance Imaging
Neoplasm Staging/methods
Reproducibility of Results
Sensitivity
and
Specificity
Urinary Bladder Neoplasms/*diagnostic imaging/*pathology
文献简介
原文链接
Comparison of survival outcomes between primary and secondary muscle-invasive bladder cancer: An updated meta-analysis
2021 年 发布于
J Robot Surg
15 卷 第 1 期
Zheng X. N.
Qiu S.
Yang L.
Wei Q.
5-alpha Reductase Inhibitors/therapeutic use
Androgen Antagonists/therapeutic use
Androgens/therapeutic use
*Carcinoma in Situ
Humans
Male
*Prostatic Neoplasms/pathology
*Urinary Bladder Neoplasms/pathology
*Androgen suppression therapy
*Androgens
*Bladder cancer
*Incidence
*Recurrence
*Systematic review
文献简介
原文链接
非肌层浸润性膀胱癌整块切除术后行二次电切意义的 Meta 分析
2021 年 发布于
国际泌尿系统杂志
39 卷 第 11 期
张兴
樊俊杰
陈宇航
王起
吴开杰
贺大林
bladder cancer
mediation
socioeconomic status
survival
systematic review
Janssen
and
undertakes research funded by UroGen Pharma
and
QED Therapeutics. We
can confirm all other authors have no conflicts of interest to declare.
文献简介
原文链接
The potential diagnosis role of TP53 mutation in advanced bladder cancer: A meta-analysis
2021 年 发布于
Urol Oncol
28 卷 第 9-10 期
Liao Y. H.
Tang H. Q.
Wang M. M.
Wang K. K.
Wang Y. Z.
Jiang N.
Data Systems
Humans
*Multiparametric Magnetic Resonance Imaging
Neoplasm Invasiveness
Predictive Value of Tests
Reproducibility of Results
Urinary Bladder Neoplasms/*diagnostic imaging/pathology
Bladder cancer
Magnetic resonance imaging
Meta-analysis
Muscle invasive
Systematic review
Vesical Imaging Reporting
and
Data System
文献简介
原文链接
对比根治性膀胱切除术与以保留膀胱手术为主的综合治疗对肌层浸润性膀胱癌疗效的 Meta 分析
2021 年 发布于
Surg Oncol
205 卷 第 12 期
邓迪豪
Adult
Aged
Aged
80
and
over
B7-H1 Antigen/genetics/*immunology
Female
Humans
Immune Checkpoint Inhibitors/*administration & dosage
*Immunotherapy
Male
Middle Aged
Programmed Cell Death 1 Receptor/genetics/*immunology
Progression-Free Survival
R
and
omized Controlled Trials as Topic
Treatment Outcome
Urinary Bladder Neoplasms/genetics/immunology/mortality/*therapy
efficacy
immunotherapy
meta-analysis
safety
urothelial cancer
this study.
文献简介
原文链接
Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text
2021 年 发布于
Can Urol Assoc J
15 卷 第 8 期
Bhindi B.
Kool R.
Kulkarni G. S.
Siemens D. R.
Aprikian A. G.
Breau R. H.
Brimo F.
Fairey A.
French C.
Hanna N.
Izawa J. I.
Lacombe L.
McPherson V.
Rendon R. A.
Shayegan B.
So A. I.
Zlotta A. R.
Black P. C.
Kassouf W.
Guidelines as Topic
Humans
Immunotherapy/*methods
Societies
Medical/*st
and
ards
Urinary Bladder Neoplasms/*drug therapy
antineoplastic protocols
immunotherapy
urinary bladder neoplasms
urologic neoplasms
Pfizer
AstraZeneca
Nektar
Seattle Genetics
DragonFly Therapeutics
Non-CME
services: Genentech
AstraZeneca
Merck
Seattle Genetics
Contracted research:
Genentech
Merck
AstraZeneca
Nektar
Seattle Genetics
Immunomedics.
PCB─Consulting fees: AbbVie
Asieris Pharmaceuticals
Astellas
AstraZeneca
Bayer
Biosyent
Bristol-Myers Squibb
EMD Serono
Ferring
Fergene
H3
Biomedicine
Janssen
Merck
Roche
Sanofi
TerSera
Urogen
Contracted research:
iProgen. MTC─Consulting fees: Pfizer
EMD Serono
AstraZeneca
Exelixis
Eisai
Seattle Genetics
Astellas
Contracted research: Exelixis
Pfizer/EMD Serono
Janssen
Apricity Health. GSD─Participant/unpaid volunteer: HealthVibe focus
group 2020. MDG─Consulting fees: Inovio
NuMab
Janssen
Merck
GlaxoSmithKline
Genentech
Bristol-Myers Squibb
Seattle Genetics
Dracen
Dragonfly
Astellas
Novartis
Pfizer
AstraZeneca
Incyte
Dendreon
Eli Lilly
EMD Serono
Aileron
Therapeutics
Ownership interest: Rappta Therapeutics
NPI: 1639140668.
PG─Consulting fees: AstraZeneca
Dyania Health
EMD Serono
Immunomedics
Janssen
Merck
Mirati Therapeutics
Genentech
Pfizer
Seattle Genetics
Contracted Research: Bavarian Nordic
Bristol-Myers Squibb
Clovis Oncology
Debiopharm
Immunomedics
Pfizer
Merck
QED Therapeutics
GlaxoSmithKline
Kure
It Cancer Research
Mirati Therapeutics. SG─Consulting fees: Merck
Bristol-Myers
Squibb
Janssen
Seattle Genetics
AstraZeneca
Contracted research:
Bristol-Myers Squibb
Pfizer
Non-CME services: Exelixis. CJH─Consulting fees:
Astellas
Bristol-Myers Squibb
Genentech
Merck
Eisai
Seattle Genetics
2bPrecise
Non-CME services: Astellas
Bristol-Myers Squibb
Genentech
Eisai
Seattle Genetics. AMK─Consulting fees: Abbott Molecular
Arquer
ArTara
Asieris
AstraZeneca
BioClin Therapeutics
Bristol-Myers Squibb
Cepheid
Cold Genesys
Eisai
Engene
Inc.
Ferring
FerGene
Imagin
Janssen
MDxHealth
Medac
Merck
Pfizer
Photocure
ProTara
Roviant
Seattle Genetics
Sessen Bio
Theralase
TMC
Innovation
US Biotest
Contracted research: Adolor
Bristol-Myers Squibb
FKD
Industries
Heat Biologics
Merck
Photocure
SWOG/NIH
SPORE
AIBCCR
Clinical
trials: FKD
Merck
Bristol-Myers Squibb
Photocure
SWOG
Adolor
Heat
Biologics
Laboratory research: NIH
SPORE
AIBCCR
Educational grant: CEC
Oncology
Editorial board: European Urology Oncology
Journal of Urology
UroToday
President of organization: International Bladder Cancer Network (IBCN)
International Bladder Cancer Group (IBCG)
IP Rights: CyPRIT (Cytokine Predictors
of Response to Intravesical Therapy) Joint with UT MD Anderson Cancer Center.
LPL─Consulting fees: Pfizer Advisory Nursing board
2018
Lecture/Speaker/Expert
Panel: ASCO Bladder Program 2019
Pfizer learning day 2019
ASCO Bladder Program
Panel Member
and
Faculty 2019
Pfizer Learning Day Speaker 2019
BCAN Webinar
Faculty 11/2020. JJM─Consulting fees: AstraZeneca
Ferring
Janssen
Nucleix
Foundation Medicine
Contracted research: Epizyme
Tesaro
Abbvie
Teaching an
endoscopy course: Olympus. ERP─Consulting fees: AstraZeneca
Infinity Pharma
Pfizer
Flatiron
Genentech
Merck
Seattle Genetics
Contracted research:
Astellas
Bristol-Myers Squibb
Genentech
Merck. JER─Consulting fees: Merck
Bristol-Myers Squibb
AstraZeneca
Astellas
Seattle Genetics
Boehringer
Ingelheim
Bayer
Pfizer
Roche/Genentech
Mirati
QED Therapeutics
Janssen
Pharmacyclics
GlaxoSmithKline
Contracted research/Clinical trial funding:
Seattle Genetics
Astellas
Roche/Genentech
Bayer
AstraZeneca
QED
Therapeutics. NS─Consulting fees: Amgen
Astellas
AstraZeneca
Bayer
Bristol-Myers Squibb
Dendreon
Fergene
Ferring
Janssen
Merck
Myovant
Nymox
Pfizer
Sanofi/Genzyme
Sesen Bio
Sun Pharma
Tolmar. GDS─Consulting fees:
Merck
Janssen
Ferring
Bristol-Myers Squibb
Pfizer
Genentech
Epivax
Oncology
AstraZeneca
Fidia
Cold Genesys
EnGene Bio
Aduro Biotech
Dendreon
FKD Therapies
CiClomed
Seattle Genetics
Urogen
PhotoCure. SITC staff:
SMW—Shares owned: Pacific Biosciences
Editas Medicine
EG
AK
BL
LL─Nothing to
disclose.
文献简介
原文链接
The association between hepatitis C virus infection and renal cell cancer, prostate cancer, and bladder cancer: a systematic review and meta-analysis
2021 年 发布于
Translational Andrology and Urology
37 卷 第 5-6 期
Ma Y. C.
Huang Z. L.
Jian Z. Y.
Wei X.
Cystectomy/adverse effects/*methods
Humans
Laser Therapy/adverse effects/*methods
Neoplasm Invasiveness
Treatment Outcome
Urethra
Urinary Bladder Neoplasms/pathology/*surgery
Bladder cancer
Laser surgery
Systematic review
and
meta-analysis
Transurethral resection
文献简介
原文链接
首页
上一页
1
2
3
4
5
6
7
8
9
下一页
尾页
共180条,每页显示
20条
50条
100条
跳转至第
页
确定